{"pageContent": "Objectives: To compare the efficacy of oral liarozole, the first retinoic acid metabolism-blocking agent (RAMBA) to be developed as differentiation therapy for human solid tumors, with that of cyproterone acetate (CPA), an antiandrogen for the treatment of metastatic prostate cancer. Liarozole promotes differentiation of cancer cells by increasing the intratumoral levels of retinoic acid.", "metaData": {"source": "Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status\nhttps://pubmed.ncbi.nlm.nih.gov/9166537/"}}